These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11206103)

  • 1. Ischaemic heart disease: clinical improvement with metabolic approach--final remarks.
    Gomes RS
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V41-3. PubMed ID: 11206103
    [No Abstract]   [Full Text] [Related]  

  • 2. Ischaemic heart disease: clinical improvement with metabolic approach.
    Ferrari R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V7-20. PubMed ID: 11206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial metabolism: pharmacological manipulation in myocardial ischaemia.
    Mitra B; Panja M
    J Assoc Physicians India; 2005 Jun; 53():552-60. PubMed ID: 16121812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["Persistent" angina: rationale for a metabolic approach].
    Marzilli M
    Ital Heart J; 2004 Mar; 5 Suppl 2():37S-41S. PubMed ID: 15074776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The malonyl CoA axis as a potential target for treating ischaemic heart disease.
    Ussher JR; Lopaschuk GD
    Cardiovasc Res; 2008 Jul; 79(2):259-68. PubMed ID: 18499682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing in heart disease.
    Dunn F; Lip G
    Practitioner; 1992 Jun; 236(1515):669-71. PubMed ID: 1454738
    [No Abstract]   [Full Text] [Related]  

  • 8. [How nitrate tolerance be prevented in the treatment of ischemic heart disease?].
    Sadowski Z; Kośmicki M
    Wiad Lek; 2000; 53(11-12):664-9. PubMed ID: 11247410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients.
    Ranchord AM; Harding SA; Pidgeon G
    Intern Med J; 2008 May; 38(5):361-4. PubMed ID: 18402563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in ischaemic heart disease].
    Alegria E; Velasco A; Azcárate P
    Rev Med Univ Navarra; 2005; 49(3):16-30. PubMed ID: 16400973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic angiogenesis - new therapy in patients with ischaemic heart disease].
    Witkowski A; Ruzyłło W
    Kardiol Pol; 2003 Apr; 58(4):328-31. PubMed ID: 14517573
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD
    Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arginine - a new effective drug in ischaemic heart disease?].
    Bednarz B
    Kardiol Pol; 2003 Sep; 59(9):248-52. PubMed ID: 14618203
    [No Abstract]   [Full Text] [Related]  

  • 14. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland.
    Byrne M; Murphy AW
    Ir Med J; 2002 Oct; 95(9):282; author reply 282-3. PubMed ID: 12470007
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.
    Clark JE; Sarafraz N; Marber MS
    Pharmacol Ther; 2007 Nov; 116(2):192-206. PubMed ID: 17765316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease.
    Najjar SS; Bottomley PA; Schulman SP; Waldron MM; Steffen RP; Gerstenblith G; Weiss RG
    J Cardiovasc Magn Reson; 2005; 7(4):657-66. PubMed ID: 16136855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New beta-blockers in the treatment of chronic ischaemic heart disease].
    Jankowski P; Kawecka-Jaszcz K; Jastrzebski M
    Przegl Lek; 2004; 61(9):955-61. PubMed ID: 15803908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ivabradin (coraxan). One more new approach to fighting myocardial ischemia in patients with ischemic heart disease].
    Eliseev OM
    Ter Arkh; 2006; 78(9):78-86. PubMed ID: 17076230
    [No Abstract]   [Full Text] [Related]  

  • 20. [Features of the effect of saturated and unsaturated fatty acids on lipid metabolism, lipoproteins, and development of ischemic heart disease].
    Ryzhenkov VE
    Vopr Pitan; 2002; 71(3):40-5. PubMed ID: 12227018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.